A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.
Open Access
- 1 September 1994
- journal article
- clinical trial
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 57 (9), 1034-1038
- https://doi.org/10.1136/jnnp.57.9.1034
Abstract
This pilot study was performed to compare the occurrence of long term motor complications in Parkinson's disease when the introduction of levodopa was delayed by an initial treatment with high doses of bromocriptine alone. The trial was a prospective randomised controlled study comparing 31 previously untreated patients with Parkinson's disease initially given bromocriptine alone to which levodopa was later added (group B/D) and 29 other previously untreated patients with Parkinson's disease immediately given levodopa alone (group D). The end point was the occurrence of the first motor complications (wearing off or dyskinesia). Group B/D patients received bromocriptine (52 (SEM 5) mg/day) for 2.7 years, to which levodopa was later added (471 (SEM 46) mg/day). Group D patients received a comparable dose of levodopa alone (569 (SEM 47) mg/day). Both had similar disability scores at the end of the study. Motor complications were fewer and appeared later in group B/D than in group D (56% after 4.9 (SEM 0.5) years of treatment v 90% after 2.7 (SEM 0.5) years, p < 0.01). Wearing off appeared later (p < 0.01) in group B/D (4.5 (SEM 0.6) years) than in group D (2.9 (SEM 0.6) years). Peak dose dyskinesia occurred less often in group B/D patients (three v 14 cases, p < 0.01). This study showed that a three year initial monotherapy with high doses of bromocriptine followed by addition of levodopa delayed the occurrence of long term motor complications usually found in patients with Parkinson's disease treated with levodopa alone from the beginning.Keywords
This publication has 33 references indexed in Scilit:
- Early combination therapy with bromocriptine and levodopa in parkinson's diseaseMovement Disorders, 1993
- Nation-Wide Collaborative Study on the Long-Term Effects of Bromocriptine in the Treatment of Parkinsonian Patients: Analysis on the Maintenance and the Change of the Original Mode of TreatmentEuropean Neurology, 1992
- Which risk factors predict the levodopa response in fluctuating Parkinson's disease?Annals of Neurology, 1990
- Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia.Journal of Neurology, Neurosurgery & Psychiatry, 1990
- The on-off phenomenon.Journal of Neurology, Neurosurgery & Psychiatry, 1989
- A randomised controlled study of bromocriptine versus levodopa in previously untreated Parkinsonian patients: a 3 year follow-up.Journal of Neurology, Neurosurgery & Psychiatry, 1989
- Motor fluctuations in Parkinson's disease: Central pathophysiological mechanisms, Part IAnnals of Neurology, 1988
- Factors that influence the occurrence of response variations in Parkinson's diseaseAnnals of Neurology, 1987
- ParkinsonismNeurology, 1967
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958